2024
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do A, Zahrawi F, Mehal W. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nature Reviews Drug Discovery 2024, 1-19. PMID: 39609545, DOI: 10.1038/s41573-024-01084-2.Peer-Reviewed Original ResearchSide effect profileTrial end pointsCombination of therapeuticsReverse many aspectsFatty acid synthase inhibitorGenetic susceptibility factorsPlacebo responseEffect profileFibrosis reversalTreated patientsClinical studiesLiver inflammationSynthase inhibitorLiver diseaseTherapeutic approachesClinical useEnd pointsSteatotic liver diseaseTherapeutic landscapeMetabolic environmentHepatocyte deathSusceptibility factorsChronic overnutritionGlobal epidemicLiverChapter 6 Clinical diagnosis and evaluation pathway
Lam R, Banini B, Do A, Lim J. Chapter 6 Clinical diagnosis and evaluation pathway. 2024, 77-100. DOI: 10.1016/b978-0-323-99649-5.00003-0.Peer-Reviewed Original Research
2023
S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease Program
Do A, Ilagan-Ying Y, Deng Y, Banini B, Lim J, Mehal W. S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease Program. The American Journal Of Gastroenterology 2023, 118: s1193-s1194. DOI: 10.14309/01.ajg.0000955964.73046.7b.Peer-Reviewed Original ResearchScreening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosisExercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Chen G, Banini B, Do A, Gunderson C, Zaman S, Lim J. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes 2023, 14: 1811. PMID: 37761951, PMCID: PMC10531443, DOI: 10.3390/genes14091811.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseEffects of exerciseFatty liver diseaseHistological outcomesLiver histologyLiver diseaseClinical trialsHistological endpointsSystematic reviewSignificant histopathological improvementNAFLD activity scoreImpact of exerciseIndependent effectsRandom-effects modelSystematic literature searchHistopathological improvementExercise interventionActivity scoreClinical endpointsPooled estimatesMeta-AnalysisTotal participantsLiterature searchComparison groupSa1547 IS TISSUE THE ISSUE? USE AND UTILITY OF LIVER BIOPSY IN A DEDICATED FATTY LIVER DISEASE CLINIC INCORPORATING METABOLIC HEALTH CARE
Ilagan-Ying Y, Tseng R, Valido K, Bollinger B, Kelly M, Do A. Sa1547 IS TISSUE THE ISSUE? USE AND UTILITY OF LIVER BIOPSY IN A DEDICATED FATTY LIVER DISEASE CLINIC INCORPORATING METABOLIC HEALTH CARE. Gastroenterology 2023, 164: s-1286-s-1287. DOI: 10.1016/s0016-5085(23)03992-6.Peer-Reviewed Original ResearchLean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI
Do A, Lim J. Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI. Hepatology 2023, 78: 6-7. PMID: 36896961, DOI: 10.1097/hep.0000000000000360.Peer-Reviewed Original ResearchBroadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine
Do A, Xu J. Broadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine. Digestive Diseases And Sciences 2023, 68: 725-728. PMID: 36670325, DOI: 10.1007/s10620-023-07827-2.Peer-Reviewed Original Research
2022
The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review
Chen G, Banini B, Do A, Lim J. The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review. Clinical And Molecular Hepatology 2022, 29: s319-s332. PMID: 36517000, PMCID: PMC10029942, DOI: 10.3350/cmh.2022.0366.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseHepatic steatosisLiver fibrosisLiver diseaseHistological endpointsIndependent effectsSystematic reviewNon-randomized interventional studyMagnetic resonance imaging-based techniquesAdditional large RCTsChronic liver diseaseSignificant histological improvementEffects of exerciseClinical outcome endpointsSystematic literature searchHistological improvementExercise interventionHepatocyte ballooningOriginal research studiesLarge RCTsOutcome endpointsInterventional studyOutcomes of Patients with Opioid-Related Diagnoses in Acute Coronary Syndrome: a National Inpatient Sample-Based Analysis
Kim Y, Pacor J, Do A, Brennan J, Fiellin D, Edelman E. Outcomes of Patients with Opioid-Related Diagnoses in Acute Coronary Syndrome: a National Inpatient Sample-Based Analysis. Journal Of General Internal Medicine 2022, 38: 563-570. PMID: 36376632, PMCID: PMC9971420, DOI: 10.1007/s11606-022-07399-3.Peer-Reviewed Original ResearchConceptsOpioid-related diagnosesPercutaneous coronary interventionCardiac arrestHospital mortalityCoronary syndromeNational Inpatient Sample databaseManagement of ACSRisk of ACSCardiovascular risk factorsOutcomes of patientsAcute coronary syndromeProportion of patientsMultivariable logistic regressionNational Inpatient SampleHospital cardiac arrestRisk of mortalityBackgroundAcute coronary syndromeOutcomes of interestT-testStudent's t-testPrimary independent variableHospital outcomesACS managementCoronary interventionOpioid useS1358 Nonalcoholic Fatty Liver Disease Outcomes in Patients With Comorbid Psychiatric Disorders Improved by Integrated Medical Weight Management and Hepatology Clinic Care
Ilagan-Ying Y, Cotter R, Bollinger B, Mehal W, Do A. S1358 Nonalcoholic Fatty Liver Disease Outcomes in Patients With Comorbid Psychiatric Disorders Improved by Integrated Medical Weight Management and Hepatology Clinic Care. The American Journal Of Gastroenterology 2022, 117: e975-e976. DOI: 10.14309/01.ajg.0000862072.84358.84.Peer-Reviewed Original ResearchS1345 Weight Loss Outcomes With and Without Diabetes in Patients With NAFLD in a Specialty Fatty Liver Disease Program
Ilagan-Ying Y, Valido K, Chehayeb R, Bollinger B, Mehal W, Do A. S1345 Weight Loss Outcomes With and Without Diabetes in Patients With NAFLD in a Specialty Fatty Liver Disease Program. The American Journal Of Gastroenterology 2022, 117: e967-e968. DOI: 10.14309/01.ajg.0000862020.76034.41.Peer-Reviewed Original ResearchS1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease
Ilagan-Ying Y, Schwartz A, Park E, Bollinger B, Ying L, Mehal W, Do A. S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease. The American Journal Of Gastroenterology 2022, 117: e1043-e1044. DOI: 10.14309/01.ajg.0000862452.53915.0f.Peer-Reviewed Original ResearchClinical Phenotyping and the Application of Precision Medicine in MAFLD
Saffo S, Do A. Clinical Phenotyping and the Application of Precision Medicine in MAFLD. Clinical Liver Disease 2022, 19: 227-233. PMID: 35795621, PMCID: PMC9248929, DOI: 10.1002/cld.1199.Peer-Reviewed Original ResearchIncreased Mortality in Patients Undergoing Inpatient Endoscopy During the Early COVID-19 Pandemic
Ilagan-Ying YC, Almeida MN, Kahler-Quesada A, Ying L, Hughes ML, Do A, Hung KW. Increased Mortality in Patients Undergoing Inpatient Endoscopy During the Early COVID-19 Pandemic. Digestive Diseases And Sciences 2022, 67: 5053-5062. PMID: 35182250, PMCID: PMC8857390, DOI: 10.1007/s10620-022-07414-x.Peer-Reviewed Original ResearchConceptsInpatient endoscopyCare centerEndoscopic proceduresIntensive care unit admissionAcademic tertiary care centerCare unit admissionProportion of patientsTertiary care centerCoronavirus disease 2019 (COVID-19) pandemicHigher mortality riskDisease 2019 pandemicEarly COVID-19 pandemicICU admissionUnit admissionPatient demographicsUrgent indicationsBlood transfusionFirst waveHigher proportionPatient reluctanceMale genderUrgent proceduresProcedural characteristicsHospital careMost healthcare systems
2021
S1125 The Impact of Dietary Composition on Non-Alcoholic Fatty Liver Disease and Advanced Fibrosis in U.S. Adults
Ochoa-Allemant P, Ilagan-Ying Y, Do A. S1125 The Impact of Dietary Composition on Non-Alcoholic Fatty Liver Disease and Advanced Fibrosis in U.S. Adults. The American Journal Of Gastroenterology 2021, 116: s529-s529. DOI: 10.14309/01.ajg.0000778032.99095.98.Peer-Reviewed Original ResearchSa623 PROVIDER KNOWLEDGE, ATTITUTDES, AND PRACTICES FOR OBESITY MANAGEMENT AMONG MEDICATION PRESCRIBERS COMPARED TO NON-PRESCRIBERS
Ilagan-Ying Y, Almeida M, Ying L, Viana A, Yang Y, Do A. Sa623 PROVIDER KNOWLEDGE, ATTITUTDES, AND PRACTICES FOR OBESITY MANAGEMENT AMONG MEDICATION PRESCRIBERS COMPARED TO NON-PRESCRIBERS. Gastroenterology 2021, 160: s-578-s-579. DOI: 10.1016/s0016-5085(21)02079-5.Peer-Reviewed Original Research921 WEIGHING THE OPTIONS: ATTITUDES AND PERCEPTIONS OF BARIATRIC SURGERY AMONGST PROVIDERS BASED ON REFERRAL PATTERNS
Ying L, Ilagan-Ying Y, Almeida M, Viana A, Yang Y, Morton J, Do A. 921 WEIGHING THE OPTIONS: ATTITUDES AND PERCEPTIONS OF BARIATRIC SURGERY AMONGST PROVIDERS BASED ON REFERRAL PATTERNS. Gastroenterology 2021, 160: s-910. DOI: 10.1016/s0016-5085(21)02912-7.Peer-Reviewed Original Research
2020
Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints
Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opinion On Drug Discovery 2020, 16: 125-134. PMID: 33086894, DOI: 10.1080/17460441.2020.1811674.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseaseNonalcoholic steatohepatitisLiver diseaseHealthcare resource burdenNovel trial designsClinical trial researchSignificant healthcareCase definitionClinical trialsEfficacious treatmentNew therapiesEndpoint definitionsTrial designTreatment targetsMetabolic diseasesTrial researchClinical researchDrug development processQuality data reportingDrug approvalDiseaseResource burdenRegulatory pathwaysDrug developmentCorrection to: Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals
Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Correction to: Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal Of General Internal Medicine 2020, 35: 3140-3140. PMID: 33021712, PMCID: PMC7572953, DOI: 10.1007/s11606-020-06227-w.Peer-Reviewed Original Research